
The IQWiG (Institute for Quality and Efficiency in Health Care)
A scientific institute under the supervision of the G-BA and the German Federal Ministry of Health. On behalf of the G-BA, the IQWiG assesses existing scientific studies and their meaningfulness under medical and statistical aspects.
IQWiG
Before the GB-A
Hearing of the manufacturer and experts; decision on the additional benefit
G-BA
Negotiation with the SHI Head Association
about the reimbursement amount. Parameters include: Decision of the G-BA on the additional benefit, price of comparable pharmaceuticals, European prices.
SHI
No agreement
Upon application, the arbitration board made up of neutral third parties determines the reimbursement amount.
Arbitration board
The dossier
At the time of market launch, the manufacturers submit a dossier to prove an additional benefit.
G-BA
Review of the dossier by the IQWiG and the G-BA within three months
New active ingredient
New active ingredient
New active ingredient
No dossier = no additional benefit
If possible, a reference price is set.
Reference price
Doctor
Hearing and decision
between the 4th and 6th month
Opt-out
The negotiations are prematurely terminated. If the manufacturer decides within 4 weeks not to offer his pharmaceutical in Germany.
Reimbursement amount negotiations
until the 12th month
Agreement
An additional benefit has been recognized. SHI and the manufacturer agree on a reimbursement amount.
Reimbursement
Doctor
Doctors can prescribe the pharmaceuticals without having to fear recourse claims (practice specialty).
Arbitration verdict
by the 15th month
Reimbursement
Manufacturer accepts the arbitration verdict
The discount determined by the arbitration board becomes effective retroactively from the 12th month.
Doctor
Manufacturer does not accept the arbitration verdict: He can withdraw the pharmaceutical from the German market or file a legal complaint about the arbitration verdict.